If you're a biotech investor, you've probably heard of both Recursion Pharmaceuticals (NASDAQ: RXRX) and CRISPR Therapeutics, (NASDAQ: CRSP) two of the most followed biotechs this year. Both companies ...

RXRX is advancing fibrosis, oncology, and neuroscience treatments via major pharma collaborations. Deals with Bayer, Roche, Sanofi, and Merck offer multi-billion milestone and royalty opportunities.

Recursion is building an industrialized engine for medicine. It operates among biotech stocks, selling access to its proprietary platform and pursuing joint development with major partners like Roche ...

Hello, everyone, and welcome to this next session on the final day of the 28th Annual Needham Growth Conference. I'm Ryan MacDonald, and I lead Needham's Healthcare Technology research efforts. And in ...

Recursion Pharmaceuticals RXRX is strategically leveraging its AI-powered drug discovery platform through multiple high-value collaborations, positioning itself for long-term growth and sustainability ...

Recursion is near the start of its growth story. In case you're not familiar, its business has three segments, but only two have any chance of yielding revenue in the near term. The company's ...